At Flare Capital Partners, we are thrilled to announce our lead investment in the latest financing round for Peer AI, a pioneering agentic AI platform transforming life sciences regulatory documentation. Today, Peer AI announced $12.1 million in total funding, led by Flare Capital Partners and SignalFire. We are also excited to be joined by our friends at Greycroft.
The Team
When investing at the earliest stages, our conviction begins with the people. Peer AI was co-founded by Anita Modi (CEO), Christopher Ceppi (CTO/COO), and Ravi Ramachandran (CSO) — a team with the rare combination of deep industry experience, technical expertise, and firsthand understanding of the regulatory documentation bottlenecks facing life sciences companies.
Anita previously served as Chief Quality and Business Transformation Officer at Science 37, where she led corporate transformation, quality, and compliance initiatives. It was there that she met Christopher, who as Chief Technology Officer built and scaled the company’s technology and R&D functions. Ravi, who had been a customer of Science 37 in his leadership roles at PPD, later joined them as Peer’s Chief Scientific Officer, bringing the perspective of someone who has brought 5+ drugs to market from the biotech and CRO side during his career.
This core team is supported by exceptional engineering talent — including former leaders from Google — as well as regulatory and medical writing professionals embedded directly into the company. They are further guided by a group of world-class advisors, including senior executives from Veeva, Databricks, MosaicML, H1, Formation Bio, and Bristol Myers Squibb. Across diligence, both existing partners and prospective customers consistently cited Peer AI’s unique blend of technical depth and domain fluency as a key differentiator.
The Market Opportunity
Documentation is a consistent and mission-critical workflow across every stage of drug development. Each new drug candidate generates 100,000 to 200,000 pages of regulatory documentation — ranging from toxicology reports and study protocols to clinical study reports and investigator brochures.
The current state of medical writing is manual, slow, and error-prone. Nearly one-third of FDA submissions contain data quality issues, and more than 70% of IND, BLA, and NDA applications are initially rejected due to incomplete or inaccurate data. These inefficiencies cause costly delays, non-compliance risks, and bottlenecks to getting life-saving therapies to patients.
Generative AI is poised to transform this landscape. According to McKinsey, AI could unlock $60B–$110B in annual value across the pharmaceutical industry, with clinical development documentation alone representing a $13B–$25B opportunity. Automating submission content could make regulatory filings 40% faster, 50% more cost-efficient, and twice as accurate. The time is ripe for innovation.
Why Peer AI
Peer AI is building a purpose-built, agentic AI platform that automates the end-to-end process of regulatory documentation — data extraction, authoring, and quality control. The “agent team” is combined with an intuitive AI-powered user interface that allows medical writers to apply their subject matter expertise at critical control points during documentation workflows. The platform integrates seamlessly into existing workflows: medical writers can upload or integrate into systems with structured and unstructured data, apply configurable templates, and generate drafts ready for multi-author review.
Customers have already seen the benefits. Peer AI has worked with large biopharma companies as well as mid-sized innovators, consistently outperforming incumbent CROs and legacy vendors.
Key features of Peer’s approach include seamless integration with existing processes, full traceability to source data for compliance, and the ability to automatically update drafts as new data becomes available.
Looking Ahead
We believe Peer AI is well-positioned to become the category-defining platform, creating an intelligent regulatory workflow that connects documentation, data, and decision-making to speed drug approvals. Its differentiated product, strong early customer validation, and exceptional founding team give us conviction in its ability to scale.
At Flare Capital, we are thrilled to partner with Anita, Chris, Ravi, and the entire Peer team as they transform how life sciences companies bring life-saving therapies to market faster, safer, and more efficiently.
To learn more about Peer AI: reach out to Ian Chiang (ian@www.flarecapital.com), Uma Veerappan (uma@www.flarecapital.com), or any member of the Flare Capital team — we would love to hear from you.
Careers: Peer AI is hiring across engineering, commercial, and product. Explore open positions here.
